Literature DB >> 10037709

Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II.

D L Becker1, J C Fredenburgh, A R Stafford, J I Weitz.   

Abstract

Assembly of ternary thrombin-heparin-fibrin complexes, formed when fibrin binds to exosite 1 on thrombin and fibrin-bound heparin binds to exosite 2, produces a 58- and 247-fold reduction in the heparin-catalyzed rate of thrombin inhibition by antithrombin and heparin cofactor II, respectively. The greater reduction for heparin cofactor II reflects its requirement for access to exosite 1 during the inhibitory process. Protection from inhibition by antithrombin and heparin cofactor II requires ligation of both exosites 1 and 2 because minimal protection is seen when exosite 1 variants (gamma-thrombin and thrombin Quick 1) or an exosite 2 variant (Arg93 --> Ala, Arg97 --> Ala, and Arg101 --> Ala thrombin) is substituted for thrombin. Likewise, the rate of thrombin inhibition by the heparin-independent inhibitor, alpha1-antitrypsin Met358 --> Arg, is decreased less than 2-fold in the presence of soluble fibrin and heparin. In contrast, thrombin is protected from inhibition by a covalent antithrombin-heparin complex, suggesting that access of heparin to exosite 2 of thrombin is hampered when ternary complex formation occurs. These results reveal the importance of exosites 1 and 2 of thrombin in assembly of the ternary complex and the subsequent protection of thrombin from inhibition by heparin-catalyzed inhibitors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10037709     DOI: 10.1074/jbc.274.10.6226

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Jeffrey I Weitz; John W Eikelboom; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Zn2+ mediates high affinity binding of heparin to the αC domain of fibrinogen.

Authors:  James C Fredenburgh; Beverly A Leslie; Alan R Stafford; Teresa Lim; Howard H Chan; Jeffrey I Weitz
Journal:  J Biol Chem       Date:  2013-08-29       Impact factor: 5.157

3.  Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex.

Authors:  Ivan Stevic; Howard H W Chan; Leslie R Berry; Ankush Chander; Anthony K C Chan
Journal:  J Biochem       Date:  2012-10-24       Impact factor: 3.387

Review 4.  Clinical pharmacology of direct and indirect factor Xa inhibitors.

Authors:  Hans-Juergen Rupprecht; Ralf Blank
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546

Review 5.  Stroke prevention treatment of patients with atrial fibrillation: old and new.

Authors:  Simerpreet Bal; Pawan Ojha; Michael D Hill
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

6.  Batroxobin binds fibrin with higher affinity and promotes clot expansion to a greater extent than thrombin.

Authors:  Trang T Vu; Alan R Stafford; Beverly A Leslie; Paul Y Kim; James C Fredenburgh; Jeffrey I Weitz
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

7.  Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin.

Authors:  Shahid M Nimjee; Sabah Oney; Zoya Volovyk; Kristin M Bompiani; Steve B Long; Maureane Hoffman; Bruce A Sullenger
Journal:  RNA       Date:  2009-10-21       Impact factor: 4.942

8.  An antithrombin-heparin complex increases the anticoagulant activity of fibrin clots.

Authors:  Lesley J Smith; Tracy Anne Mewhort-Buist; Leslie R Berry; Anthony K C Chan
Journal:  Res Lett Biochem       Date:  2008-04-14

9.  Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function.

Authors:  Calvin H Yeh; Alan R Stafford; Beverly A Leslie; James C Fredenburgh; Jeffrey I Weitz
Journal:  PLoS One       Date:  2016-06-15       Impact factor: 3.240

Review 10.  Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.

Authors:  Ravi K Ramana; Bruce E Lewis
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.